betaliq – Innovating glaucoma treatments

Betaliq Inc.

Innovating glaucoma treatments

About us

Betaliq, Inc. is a clinical-stage pharmaceutical company dedicated to transforming glaucoma treatment. By leveraging cutting-edge technology and patient-centric innovation, we aim to address significant unmet needs in eye care and enhance the quality of life for millions worldwide.

Founded in 2018 through a strategic collaboration between BLP Management Group and Novaliq GmbH, Betaliq is redefining topical ophthalmic therapies with a strong focus on safety, efficacy, and innovation. Through this partnership, we hold exclusive rights to Novaliq’s proprietary EyeSol^® technology – a water-free drug delivery platform designed to optimize treatment outcomes – for glaucoma therapies. With a vision for expansion, Betaliq is well-positioned to build a portfolio of Glaucoma therapies and to expand into other indications within general ophthalmology and specialty eye care through partnerships.

Our lead drug candidate, BTQ1902, is a timolol suspension formulated with EyeSol^®. Following positive Phase 2a data, we are advancing towards Phase 3 clinical trial, bringing us closer to providing an effective and well-tolerated treatment option for glaucoma patients.

Since our inception, Betaliq has built a strong foundation for success, attracting investor confidence and securing key funding milestones. In 2019, we completed an $8 million Series A funding round, led by Brookline Capital Markets.

Our virtual management model has allowed us to efficiently allocate resources, drive innovation, and remain agile as we approach critical milestones, including the completion of Phase 2 as well as the planned Phase 3 trial for BTQ1902.

Glaucoma

Glaucoma is a growing global health challenge and market opportunity

Glaucoma is a leading cause of irreversible blindness worldwide, affecting over 80 million people as of 2020, with numbers projected to exceed 111 million by 2040. Characterized by progressive damage to the optic nerve over time caused from backup of fluid in the eye leading to elevated pressure, called intraocular pressure (IOP), glaucoma remains asymptomatic until advanced stages, underscoring the need for early diagnosis and effective treatment solutions.

Our commitment to advancing glaucoma therapies

Despite the availability of various treatments – including eye drops, laser therapy, and surgical interventions – current options often suffer from limitations such as poor patient adherence, side effects, and incomplete IOP control.

Our commitment to advancing glaucoma therapies

Our pharmaceutical pipeline is focused on addressing the most pressing gaps in glaucoma care. Through novel formulations based on EyeSol^®, we are dedicated to improving patient outcomes and enhancing quality of life. With a strong commitment to research and development, strategic partnerships, and operational expertise, we are positioned at the forefront of the next wave of glaucoma treatment solutions.

Technology

Betaliq’s programs are built on EyeSol^®, the worldwide first and only water-free technology for ophthalmic products licensed from Novaliq. EyeSol^® addresses the limitations of traditional water-based eye drops and offers improved therapeutic outcomes for a range of eye conditions.

The challenge with traditional water-based eye drops

Water is often the main ingredient in eye drops, serving as a base for other components. These water-based eye drops dispense drops of 40–50 µL, far exceeding the eye’s capacity, leading to spillover and loss of medication. Additionally, the natural surface tension of water and the outer lipid layer of the tear film limit drug spreading on the ocular surface. Moreover, water-based eye drops trigger the eye’s defense mechanisms, causing rapid blinking and tear secretion, further reducing drug retention. All these factors reduce the retention time and contribute to a relatively low bioavailability of traditional topical ophthalmic medications, which is reported to be between 1-10%.

EyeSol^®: A New Standard in Ophthalmic Drug Delivery

By addressing these challenges, EyeSol® redefines topical ophthalmic treatments, ensuring longer retention, better absorption, and improved patient outcomes.

Key features of EyeSol^®

Extended Residual Time: Significantly prolongs the time the formulation remains on the eye, increasing from minutes to hours.
High Bioavailability: Enhances the absorption of active pharmaceutical ingredients (APIs) for improved therapeutic effects.
Excellent Tolerability and Safety: Demonstrates a strong safety profile with minimal adverse reactions.
Minimized Systemic Exposure: The small drop size reduces systemic absorption, enhancing patient safety.
Preservative-free: EyeSol^®‘s water-free formulation eliminates the need for preservatives, minimizing irritation and adverse effects.
Ocular Surface Beneficial: Supports the health and integrity of the ocular surface.

EyeSol^® is clinically validated and safe tested in more than 2,500 patients. It is physically, chemically, and physiologically inert, undergoes no catabolism or metabolism and is highly biocompatibility with no bioaccumulation.

EyeSol^® technology has been successfully utilized in a range of products that have received FDA and EMA approvals, as well as CE certification, including:

MIEBO^© (perfluorohexyloctane ophthalmic solution)
VEVYE^© (cyclosporine ophthalmic solution) 0.1%
VEVIZYE^© (ciclosporin 0.1% eye drops solution)
NovaTears^©/EvoTears^©
NovaTears^©/EvoTears^©+Omega-3

Pipeline

Our goal is to establish a comprehensive pipeline of next-generation topical drugs based on our proprietary EyeSol^® technology.

DLQ01

Segment	Product Code	Product Rights	Phase II	Phase III
Elevated Intraocular Pressure (Glaucoma)	BTQ1902 (timolol 0.5% suspension in perfluorohexyloctane)	Global	completed	1 single trial
	BTQ2301 (latanoprost solution in EyeSol^®	Global
				accelerated development
	BTQ2302 (timolol & latanoprost combination)	Global

BTQ1902

BTQ1902 ophthalmic suspension (timolol in perfluorohexyloctane) 0.5% is our lead clinical product in development for the treatment of elevated intraocular pressure in patients with primary open angle glaucoma or ocular hypertension.

BTQ1902 contains timolol maleate 0.5% suspended in EyeSol^®. Utilizing EyeSol^® as the vehicle for ophthalmic suspension allows development of the product as a non-preserved suspension in a multi-dose bottle, minimizing tolerability and ocular irritation issues due to the lack of other excipients such as preservatives or phosphates.

Key Advantages of BTQ1902 over existing timolol therapies

Less drug exposure due to >60% smaller drop size at equal efficacy (clinically demonstrated)
Water-free, non-preserved in multi-dose bottle
More drops per volume allows to develop multi-month supply in a single bottle
Vehicle with proven efficacy & safety in dry eye disease
Novel suspension with long-lasting patent protection

The Phase 2 clinical trial results for BTQ1902 ophthalmic suspension (timolol in perfluorohexyloctane) 0.5% in patients with open-angle glaucoma or ocular hypertension revealed a clinically meaningful reduction in intraocular pressure (IOP). BTQ1902 not only met the study’s objective of statistical non-inferiority but also confirmed its efficacy and safety profile are comparable to the established standard of Timolol 0.5%. Furthermore, participants tolerated BTQ1902 well, demonstrating an excellent safety profile throughout the trial.

Following these promising results, the FDA confirmed that a single Phase 3 trial will be sufficient for New Drug Application (NDA) submission, accelerating the path toward potential approval.